Upcoming Webinar :Register now for 'ULIP as an investment during economic recovery' powered by Bajaj Allianz

Buy Ipca Laboratories: Target Of Rs 2560: Sharekhan

Sharekhan is bullish on Ipca Laboratories recommended buy rating on the stock with a target price of Rs 2560 in its research report dated November 09, 2020.

Nov 11, 2020 / 11:26 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sharekhan's research repor on Ipca Laboratories


Ipca Laboratories Limited (Ipca) clocked strong numbers in Q2FY21 with sales growing 6% y-o-y to Rs 1,361 crore while PAT was up by 38.3% y-o-y to Rs. 267 crore. API segment has immense growth opportunities ahead, as company sees strong demand traction in this segment and is implementing de-bottlenecking to ease out capacity constraints. Formulations segment’s revenues also expected to improve backed by a pick-up in domestic as well as exports markets. Strong earnings prospects, sturdy balance sheet and healthy return ratios bode well.


Outlook


We retain a Buy on stock with a revised PT of Rs 2,560.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Nov 11, 2020 11:26 am

stay updated

Get Daily News on your Browser
Sections